<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100576</url>
  </required_header>
  <id_info>
    <org_study_id>TMED_INZULIN_001</org_study_id>
    <nct_id>NCT05100576</nct_id>
  </id_info>
  <brief_title>Intensified Insulin Therapy With Telemedicine</brief_title>
  <official_title>Randomized Controlled Clinical Trial of Telemedicine-guided Lifestyle Intervention in Diabetic Patients During Intensive Insulin Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Szeged University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the effect of a 3-month telemedicine-led lifestyle intervention in&#xD;
      individuals requiring intensified insulin therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to evaluate the development of HbA1c levels in&#xD;
      patients requiring 3 months of intensified insulin therapy using standard therapy and&#xD;
      telemedicine devices currently in use.&#xD;
&#xD;
      The telemedicine system contains a mobile phone-based nutrition diary, bluetooth-related&#xD;
      wrist activity meter, weight scale, blood pressure monitor, blood glucose meter, and IT&#xD;
      system for transmitting and displaying data from these devices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c level</measure>
    <time_frame>3 months</time_frame>
    <description>Investigation of the effect of a 3-month telemedicine-led lifestyle intervention on HbA1c levels in individuals requiring insulin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 months</time_frame>
    <description>Safety of the device system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of hypoglycemic episodes</measure>
    <time_frame>3 months</time_frame>
    <description>Number of hypoglycemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the decisions between the two type of visits</measure>
    <time_frame>3 months</time_frame>
    <description>Consistency of investigators' decisions based on telemedicine data and personal visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intensified Insulin Therapy</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group gets the telemedicine system, with the devices, and gets life-style guide by telephone consultation/ visits, during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group gets the normal, evidence based therapy, without extra visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Telemedicine system users</intervention_name>
    <description>Telemonitoring by medical devices connected to a software system with a router.</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women or men between the ages of 18 and 75&#xD;
&#xD;
          -  Patient with Diabetes who needs intensified insulin therapy HbA1c&gt; = 8%&#xD;
&#xD;
          -  IT proficiency is at least basic for cell phones (answering / making a voice call).&#xD;
&#xD;
          -  Signing a informed consent&#xD;
&#xD;
          -  For women with childbearing potential, by definition, all women who who are&#xD;
             physiologically able to conceive are twofold use of contraception&#xD;
&#xD;
          -  The subject communicates well with the investigator and is able to perform the test to&#xD;
             understand and help comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  informed refusal any time after the sign of the informed consent&#xD;
&#xD;
          -  Planned invasive cardiac intervention (catheter vasodilation or surgical coronary&#xD;
             artery bypass grafting, keyboard surgery or replacement)&#xD;
&#xD;
          -  Tumor disease&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any medical condition that does not allow participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>István Kósa, Md Ph.D.</last_name>
    <phone>+36 70 320 1192</phone>
    <email>office.prevmedicina@med.u-szeged.hu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>István Kósa, MD Ph.D.</last_name>
      <phone>+36 70 320 1192</phone>
      <email>office.prevmedicina@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Csaba Lengyel, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>István Kósa, MD Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>telemedicine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

